Common Stock, par value $0.01 per share
- Symbol
- MNKD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
MannKind Corporation
MNKDNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On August 21, 2026, MannKind Corporation (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the Securities and Exchange Commission.…
Company context
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Current securities
Historical securities (1)
Registered securities in this filing
MANNKIND CORP · 8-K · Filed 2026-08-21
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On August 21, 2026, MannKind Corporation (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the Securities and Exchange Commission. This Current Report on Form 8-K is being filed for the purpose of filing the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares of common stock of the Company set forth in the prospectus supplement, which opinion is filed as Exhibit 5.1 hereto.